NCT03552471 2025-02-13Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerOhio State University Comprehensive Cancer CenterPhase 1 Completed25 enrolled